ArticleEuropean journal of medical research2025
Knockdown of FXYD2 inhibits mepivacaine-induced cardiomyocyte injury by activating the PI3K/AKT signaling pathway.
Article in European journal of medical research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMyocardial infarction (MI) is a severe cardiovascular event associated with various molecular alterations. This study aimed to explore the intricate relationship between mepivacaine, a local anesthetic, and MI by identifying and characterizing overlapping genes through a comprehensive analysis.
methodsDifferential expression analysis was performed using the GSE19339 data set to identify overlapping genes between MI and mepivacaine, and functional enrichment analysis as well as expression verification was performed. Rat cardiomyocyte H9c2 cells were divided into four groups: control, a model group (mepivacaine), treatment (si-FXYD2 + mepivacaine) and PI3K inhibitor group (si-FXYD2 + mepivacaine + LY294002). In vitro analysis of the effects of FXYD2 regulation on the viability, of Lactate dehydrogenase (LDH) release, Reactive oxygen species (ROS) generation, PI3K/AKT signaling pathway activation, oxidative stress, apoptosis, mitochondrial respiratory chain activity, and endoplasmic reticulum (ER) stress of mepivacaine-treated H9c2 cells.
resultsEight genes were identified linking MI to mepivacaine, with FXYD2 notably upregulated in MI samples. In vitro experiments confirmed that FXYD2 knockdown in H9c2 cells significantly alleviated the mepivacaine-induced decrease in cell viability and oxidative stress, as well as the increase in apoptosis (p < 0.05). Knocking down FXYD2 inhibits mepivacaine-induced mitochondrial damage, effectively alleviates endoplasmic reticulum stress under mepivacaine treatment, and reduces the expression of stress markers (GRP78, CHOP). These cellular protections are mediated through the PI3K/AKT signaling pathway, whose activation is modulated by FXYD2 expression and mepivacaine treatment (p < 0.05).
conclusionsKnockdown of FXYD2 plays a key role in reducing mepivacaine-induced cardiomyocyte injury by modulating oxidative stress, apoptosis, mitochondrial function, and ER stress, mediated through the PI3K/AKT signaling cascade.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.